Latest news with #DanielODay
Bloomberg
3 days ago
- Health
- Bloomberg
Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value
Gilead Sciences Inc. Chief Executive Officer Daniel O'Day said the company's new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump administration will handle recommendations for treatments like this. 'It's a very straightforward economic argument to prevent the disease,' O'Day said in an interview at Bloomberg's headquarters in New York Friday. 'No one wants HIV to continue to expand in this country.'
Yahoo
5 days ago
- Business
- Yahoo
Gilead Sciences's Q2 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention. Management attributed the 7% year-over-year HIV growth to robust demand for Biktarvy and Descovy, along with effective commercial execution. CEO Daniel O'Day highlighted, 'Biktarvy continues to lead in share in major markets around the world,' and described Descovy's quarter as its 'strongest ever,' supported by heightened awareness and growing use of pre-exposure prophylaxis (PrEP). The company also noted that new product launches, particularly Yeztugo, contributed to positive momentum, while declines in Veklury sales due to reduced COVID-19 hospitalizations partially offset gains in the base business. Is now the time to buy GILD? Find out in our full research report (it's free). Gilead Sciences (GILD) Q2 CY2025 Highlights: Revenue: $7.08 billion vs analyst estimates of $7.00 billion (1.8% year-on-year growth, 1.1% beat) Adjusted EPS: $2.01 vs analyst estimates of $1.96 (2.7% beat) Adjusted EBITDA: $3.87 billion vs analyst estimates of $4.02 billion (54.7% margin, 3.6% miss) The company slightly lifted its revenue guidance for the full year to $28.5 billion at the midpoint from $28.4 billion Management raised its full-year Adjusted EPS guidance to $8.10 at the midpoint, a 2.5% increase Operating Margin: 34.9%, down from 38% in the same quarter last year Market Capitalization: $149.1 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Our Top 5 Analyst Questions From Gilead Sciences's Q2 Earnings Call Tyler Van Buren (TD Cowen) asked about the early uptake trajectory for Yeztugo and whether initial prescriptions would grow linearly or accelerate. Chief Commercial Officer Johanna Mercier said the launch was 'super thrilled to see' but noted it was still early, emphasizing high prescriber engagement and the process of building access across plans. Terence C. Flynn (Morgan Stanley) inquired about the durability of Descovy's growth rate and visibility of PrEP market trends. Mercier explained that robust PrEP market growth and improved access were key, but anticipated that as Yeztugo gains traction, a shift in product mix could occur. Umer Raffat (Evercore) questioned the impact of potential Medicaid policy changes, such as Most Favored Nation proposals, on Gilead's revenue. CEO Daniel O'Day acknowledged industry uncertainty and highlighted that HIV's safety net programs provide some protection, but broader policy changes remain a risk. Chris Schott (JPMorgan) sought clarification on the status of the WONDERS weekly HIV treatment program, which is on clinical hold. Chief Medical Officer Dietmar Berger said confidence in the pipeline remains high, with ongoing analysis to determine next steps for the program and updates expected in due course. Courtney Breen (Bernstein) followed up on why management did not raise Yeztugo launch expectations despite positive early access and uptake indicators. Mercier explained that the launch is only six weeks in and more time is needed to see sustained coverage and prescription momentum before updating guidance. Catalysts in Upcoming Quarters In the coming quarters, the StockStory team will monitor (1) the adoption curve and access expansion for Yeztugo in both U.S. and international PrEP markets, (2) pivotal clinical updates for ARTISTRY-1 and ARTISTRY-2, which could support new HIV treatment regimens, and (3) regulatory filings and data readouts for Trodelvy and anito-cel in oncology and cell therapy. Progress in reimbursement negotiations and updates on policy risk management will also be important indicators of execution. Gilead Sciences currently trades at $120.22, up from $110.36 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). Our Favorite Stocks Right Now Donald Trump's April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don't miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-08-2025
- Business
- Yahoo
Gilead posts flat quarterly profit, raises full-year outlook
By Deena Beasley (Reuters) -Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial outlook due largely to better-than-expected sales of HIV drugs. Adjusted earnings per share were flat from a year earlier at $2.01, and just ahead of the average analysts' estimate of $1.97, as compiled by LSEG. Revenue rose 2% from a year earlier to $7.1 billion, which was in line analysts' expectations. Gilead did not disclose sales of Yeztugo, a twice-yearly HIV prevention drug approved by U.S. regulators in June. CEO Daniel O'Day told Reuters that the company is very happy with the launch so far. "The first scrip was written within hours... the first dose was delivered within days," he said, adding that the company is on track to achieve its stated goal of 75% insurer coverage of the drug within six months and 90% coverage within a year. Total HIV product sales for the quarter rose 7% year-over-year to $5.1 billion. Gilead said its second-quarter cell therapy sales fell 7% to $485 million due to increased competition, while sales of cancer drug Trodelvy rose 14% to $364 million. Sales of Gilead's portfolio of liver disease treatments fell 4% to $795 million, driven mainly by lower sales of hepatitis C drugs. For the full year, Gilead said it now expects adjusted earnings per share of $7.95 to $8.25, up from its previous estimate of $7.70 to $8.10. The company also bumped up its expectations for 2025 product sales to between $28.3 billion and $28.7 billion from a previous range of $28.2 billion to $28.6 billion. Gilead Chief Financial Officer Andrew Dickinson attributed the new outlook to better-than-expected HIV sales and expense discipline. Analysts have forecast full year earnings of $8.01 per share on revenue of $28.7 billion. (Reporting By Deena BeasleyEditing by Bill Berkrot) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
07-08-2025
- Business
- Reuters
Gilead posts flat quarterly profit, raises full-year outlook
Aug 7 (Reuters) - Gilead Sciences (GILD.O), opens new tab on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial outlook due largely to better-than-expected sales of HIV drugs. Adjusted earnings per share were flat from a year earlier at $2.01, and just ahead of the average analysts' estimate of $1.97, as compiled by LSEG. Revenue rose 2% from a year earlier to $7.1 billion, which was in line analysts' expectations. Gilead did not disclose sales of Yeztugo, a twice-yearly HIV prevention drug approved by U.S. regulators in June. CEO Daniel O'Day told Reuters that the company is very happy with the launch so far. "The first scrip was written within hours... the first dose was delivered within days," he said, adding that the company is on track to achieve its stated goal of 75% insurer coverage of the drug within six months and 90% coverage within a year. Total HIV product sales for the quarter rose 7% year-over-year to $5.1 billion. Gilead said its second-quarter cell therapy sales fell 7% to $485 million due to increased competition, while sales of cancer drug Trodelvy rose 14% to $364 million. Sales of Gilead's portfolio of liver disease treatments fell 4% to $795 million, driven mainly by lower sales of hepatitis C drugs. For the full year, Gilead said it now expects adjusted earnings per share of $7.95 to $8.25, up from its previous estimate of $7.70 to $8.10. The company also bumped up its expectations for 2025 product sales to between $28.3 billion and $28.7 billion from a previous range of $28.2 billion to $28.6 billion. Gilead Chief Financial Officer Andrew Dickinson attributed the new outlook to better-than-expected HIV sales and expense discipline. Analysts have forecast full year earnings of $8.01 per share on revenue of $28.7 billion.
Fox News
19-06-2025
- Health
- Fox News
FDA approves first twice-yearly injection that prevents HIV infection
The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday. Sold under the name Yeztugo, the company's injectable HIV-1 capsid inhibitor (lenacapavir) reduces the risk of sexually acquired HIV in adults and adolescents. "This is a historic day in the decades-long fight against HIV," said Daniel O'Day, chairman and CEO of California-based Gilead Sciences, in a press release. The medicine, which only needs to be administered twice a year, has shown "remarkable outcomes in clinical studies," as Gilead claims it could transform HIV prevention. The drug is given as an injectable under the skin that the body then slowly absorbs. Individuals must have a negative HIV-1 test prior to starting the treatment. In large trials last year, the drug was not only nearly 100% effective in its prevention of HIV, but proved superior to once-daily oral medication like Truvada, another drug by Gilead. The journal Science named lenacapavir its 2024 "Breakthrough of the Year." Lenacapavir uses a multi-stage approach that distinguishes it from other approved antiviral medications. "While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle," states the press release from Gilead. For more Health articles, visit "Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," O'Day said in the press release. The most commonly reported adverse reactions during clinical trials included injection site reactions, headache and nausea, according to the company.
